KFAS
HAE icon

Keating Financial Advisory Services’s Haemonetics HAE Stock Holding History

Keating Financial Advisory Services’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73K Buy
23
+1
+5% +$64 ﹤0.01% 1995
2026
Q1 		$1.24K Buy
22
+5
+29% +$326 ﹤0.01% 2016
2025
Q4 		$1.36K Buy
+17
New +$1.14K ﹤0.01% 1709

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's HAE Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Haemonetics (HAE) stake by 4.5% in Q2 2026, buying an estimated $64 and bringing the position to 23 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1995.

Keating Financial Advisory Services first reported a position in HAE in Q4 2025 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Keating Financial Advisory Services held 23 shares of Haemonetics worth $1.73K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Haemonetics share in Q2 2026, an estimated $64.
  • Haemonetics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1995 holding.
  • Keating Financial Advisory Services first reported a position in Haemonetics in Q4 2025 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.